别嘌醇治疗与前列腺癌风险的荟萃分析。

A meta-analysis of allopurinol therapy and the risk of prostate cancer.

机构信息

Department of Public Health, College of Public Health, and School of Medicine, College of Medicine, China Medical University, Taichung, Taiwan,Department of Family Medicine, China Medical University Hospital, Taichung, Taiwan,Department of Occupational Safety and Health, College of Public Health, China Medical University, Taichung, Taiwan,Department of Research, Taichung Tzu Chi Hospital, Taichung, Taiwan,School of Medicine, College of Medicine, China Medical University, Taichung, Taiwan,Department of Family Medicine, China Medical University Hospital, Taichung, Taiwan,College of Medicine, Tzu Chi University, Hualien, Taiwan,Division of Hepatogastroenterology, Department of Internal Medicine, Taichung Tzu Chi Hospital, Taichung, Taiwan.

出版信息

Medicine (Baltimore). 2022 Mar 18;101(11). doi: 10.1097/MD.0000000000028998.

DOI:10.1097/MD.0000000000028998

PMID:35356907

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10684161/

Abstract

OBJECTIVE

: The aim of the study was to investigate the risk of prostate cancer among people with gout and/or hyperuricemia who used allopurinol and who did not use allopurinol.

METHODS

: We conducted a meta-analysis to identify the cohort and case-control studies by searching PubMed and Web of Science. We used the random-effects model to calculate the pooled risk ratio with 95% confidence interval for the risk of prostate cancer associated with allopurinol treatment.

RESULTS

: There were 5 cohort studies and 2 case-control studies included in the meta-analysis. All 7 eligible studies were published between 2012 and 2021. The study period ranged from 8 to 13years. The number of study subjects ranged from 25,770 to 1,623,550. The age of study subjects ranged from 20 to 99years. Overall, allopurinol treatment was not associated with the risk of prostate cancer (risk ratio = 1.13, 95% confidence interval = 0.96-1.34 and = .13). The heterogeneity was high between studies (I = 93%).

CONCLUSIONS

: Our meta-analysis reveals that no association can be found between allopurinol treatment and the risk of prostate cancer among people with gout and/or hyperuricemia. We propose that the inhibition of xanthine oxidase and the reduction of serum uric acid via allopurinol treatment do not affect the probability of developing prostate cancer. Further studies are needed to confirm our findings.

KEY POINTS

No association can be found between allopurinol treatment and the risk of prostate cancer. The inhibition of xanthine oxidase and the reduction of serum uric acid via allopurinol treatment do not affect the probability of developing prostate cancer.

摘要

目的

本研究旨在探讨痛风和/或高尿酸血症患者使用别嘌醇和未使用别嘌醇的情况下，患前列腺癌的风险。

方法

我们通过检索 PubMed 和 Web of Science 进行荟萃分析，以确定队列和病例对照研究。我们使用随机效应模型计算与别嘌醇治疗相关的前列腺癌风险的汇总风险比及其 95%置信区间。

结果

共有 5 项队列研究和 2 项病例对照研究纳入荟萃分析。所有 7 项合格研究均发表于 2012 年至 2021 年期间。研究时间范围为 8 至 13 年。研究对象数量范围为 25770 至 1623550 人。研究对象年龄范围为 20 至 99 岁。总体而言，别嘌醇治疗与前列腺癌风险无关（风险比=1.13，95%置信区间=0.96-1.34， =.13）。研究之间存在高度异质性（I = 93%）。